Home health remedies AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva


AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.

Wednesday, the FDA approved a combination of the drug and Roche’s Gazyva for previously untreated patients with CLL or small lymphocytic leukemia (SLL). The regimen, approved speedily under the agency’s Real-Time Oncology Review, represents a chemo-free option for patients.

RELATED: Yet another AbbVie-Roche regimen, this time with Venclexta and Gazyva, hits its marks in CLL

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

“Some patients are unable to tolerate chemotherapy regimens due to their underlying health,” Roche’s chief medical officer and head of global product development, Sandra Horning, M.D., said in an October statement after the companies unveiled top-line results.

The approval comes on the back of strong phase 3 data that showed the combo could cut the risk of disease worsening or death by 67% compared with Gazyva plus chlorambucil, a current standard of care. And it’s not the first the partners have collected within the last year; last June, they picked up an FDA approval for a marriage of Venclexta and Roche megablockbuster Rituxan, the predecessor to Gazyva, in previously treated CLL patients.

RELATED: Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients

Both those green lights will help Venclexta toward the $2 billion peak sales mark that analysts have predicted for the drug. But at least for now, multiple myeloma indications won’t. In March, deaths in trials prompted U.S. regulators to halt enrollment of all of Venclexta’s myeloma trials; they later revealed that a combination of Venclexta, Takeda proteasome inhibitor Velcade and dexamethasone had doubled patients’ relative risk of death compared with placebo.

Source link


Please enter your comment!
Please enter your name here

17 + twelve =